Abstract
Background Tertiary student men who have sex with men (TSMSM) may engage in behaviors that increase their risk of infection with human immunodeficiency virus (HIV) and sexually transmitted infections (STI). Respondent-driven sampling (RDS) has become a popular method for discretely recruiting marginalized populations into HIV/STI research. We conducted formative research to assess appropriateness and acceptability of RDS in recruiting TSMSM into a prospective HIV/STI bio-behavioral survey in Nairobi, Kenya.
Methods Between September and October 2020, semi-structured qualitative interviews were held with service providers from organizations that serve MSM (n=3), and TSMSM (n=13). Interviews explored social networks of TSMSM, acceptability of using RDS as a sampling method, potential RDS implementation challenges, and proposed solutions to these challenges. Interviews were done in English, audio-recorded and transcribed then analyzed thematically using NVivo version 11.
Results Service providers reflected that TSMSM had large though concealed networks, thus making RDS an appropriate sampling method. Risk of ineligible persons attempting to participate due to the associated double incentive was noted, and using student identification documents as part of eligibility screening recommended. TSMSM also perceived RDS to be an acceptable strategy based on their large social network sizes (10-40), and the trust amongst themselves. TSMSM were concerned about participating due to the risk of being outed as MSM, seeing as same sex behavior is criminalized in Kenya, and hence emphasized that researchers needed to assure them of their confidentiality, and include MSM as part of the study team to encourage participation. TSMSM suggested coupons should indicate value of reimbursement, be pocket-sized and placed in an envelope to avoid loss, and provide directions to and contacts of the survey site for easy access.
Conclusion RDS was perceived as both an appropriate and acceptable sampling method. Anticipated challenges of RDS implementation were highlighted, and possible solutions to these challenges suggested.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.frontiersin.org/article/10.3389/fpubh.2021.619694
Funding Statement
SM was supported by the Consortium for Advanced Research Training in Africa (CARTA). CARTA is jointly led by the African Population and Health Research Center and the University of the Witwatersrand and funded by the Carnegie Corporation of New York (Grant No-G-19-57145), Sida (Grant No:54100113), Uppsala Monitoring Centre and the DELTAS Africa Initiative (Grant No: 107768/Z/15/Z). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS) Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (UK) and the UK government. The statements made and views expressed are solely the responsibility of the Fellow.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was reviewed and approved by University of the Witwatersrand Human Research Ethics Committee-Medical (Reference number: M200215) and University of Nairobi-Kenyatta National Hospital Ethics and Research Committee (Reference number: P990/12/2019).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
